FASS logotyp
Receptbelagd

Peka på symbolerna och beteckningarna till vänster för en förklaring.

Kontakt

Sök apotek med läkemedlet i lager

Sök lagerstatus

Pulmicort®

AstraZeneca

Suspension för nebulisator 0,5 mg/ml
(vitaktig suspension)

Inflammationshämmande läkemedel för inhalation vid astma

Aktiv substans:
ATC-kod: R03BA02
Läkemedel från AstraZeneca omfattas av Läkemedelsförsäkringen.
  • Vad är miljöinformation?

Miljöinformation

Miljöpåverkan

Budesonid

Miljörisk: Risk för miljöpåverkan av budesonid kan inte uteslutas då det inte finns tillräckliga ekotoxikologiska data.
Nedbrytning: Budesonid bryts ned i miljön.
Bioackumulering: Budesonid har låg potential att bioackumuleras.


Läs mer

Detaljerad miljöinformation

PEC/PNEC = 0.008µg/L /8.60µg/L = 0.00092


Environmental Risk Classification


Predicted Environmental Concentration ( PEC)


PEC is based on the following data and calculated using the equation outlined in the fass.se guidance (Ref 1):


PEC (µg/L)      = (A*109*(100-R))/(365*P*V*D*100)

PEC (µg/L)      = 1.37*10-6*A*(100-R)

PEC                 = 1.37* 10-6 *57.657 * (100-0) = 0.008 µg/L


A (Kg/year)      = total sold amount API in Sweden year 2021, data from IQVIA/Lif.

                        = 57.657 kg/year

R (%)               = removal rate (due to loss by adsorption to sludge particles, by volatilization, hydrolysis or biodegradation = 0 (default)

P                      = number of inhabitants in Sweden = 10*106 (default, Ref 1)

V (L/day)         = volume of wastewater per capita and day

= 200 (default, Ref 1)

D                     = factor for dilution of waste water by surface water flow = 10 (default, Ref 1)

(Note: The factor 109 converts the quantity used from kg to μg)


Metabolism and excretion

After oral inhalation budesonide undergoes an extensive degree (>90%) of biotransformation to metabolites of low corticosteroid activity on first passage through the liver. The activity of the major metabolites, 6β-hydroxy-budesonide and 16α-hydroxy-prednisolone, is less than 1% of the parent compound. The plasma elimination half-life is approximately 4 hours. Unchanged budesonide has not been detected in urine (Ref 2). As such, environmental exposure of budesonide resulting from patient use is expected to be negligible; however the PEC does not take into consideration metabolism and therefore provides a worst-case exposure senario.


PNEC (Predicted No Effect Concentration)


Ecotoxicity Data

Study Type

Method

Result

Reference

Activated sludge, respiration inhibition test 

OECD 209

3 hour EC50 >1000 mg/L

3 hour NOEC = 1000 mg/L

3

Toxicity to green algae, Selenastrum capricornutum growth inhibition test

OECD 201

72 hour NOEC (growth rate) = 5.6 mg/L

72 hour LOEC (growth rate) = 8.6 mg/L

72 hour EC50 (growth rate) > 8.6 mg/L


72 hour NOEC (biomass) = 5.6 mg/L

72 hour LOEC (biomass) = 8.6 mg/L

72 hour EC50 (biomass) > 8.6 mg/L

4

Growth inhibition study Pseudokirchneriella subcapitata

(previously Selenastrum capricornutum)


OECD 201

72 hour NOEC (growth rate) = 7.9 mg/L

72 hour LOEC (growth rate) > 7.9 mg/L

72 hour EC50 (growth rate) > 7.9 mg/L


72 hour NOEC (biomass) = 7.9 mg/L

72 hour LOEC (biomass) > 7.9 mg/L

72 hour EC50 (biomass) > 7.9 mg/L

5

Daphnia magna reproduction test under semi-static conditions

OECD 211

21 day NOEC = 6.95mg/L

21 day LOEC < 6.95mg/L

6

Acute toxicity to the giant water flea, Daphnia magna

OECD 202

48 hour EC50 (immobility) >14 mg/L

48 hour NOEC (immobility) = 3.8mg/L

7

Acute toxicity to Rainbow Trout, Oncorhynchus mykiss

OECD 203

96 hour LC50 (mortality) > 13 mg/L

96 hour NOEC (mortalitiy) = 13mg/L

8

Fish Life cycle test

Danio rerio

Bespoke

F0 generation

Early life stage:

NOEC ≥ 3200 ng/L hatch, day 28 survival and length

Juvenile growth stage:

NOEC = 1000 ng/L length at day 56 (mechanistically

appropriate NOEC)

NOEC ≥ 3200 ng/L survival

Reproduction:

NOEC ≥ 3200 ng/L based on time to spawning, total egg number,

eggs/female and fertilization rate

Test termination:

NOEC ≥ 3200 ng/L for survival, length, weight, sex ratio,

vitellogenin, 11-keto-testosterone

F1 generation

Early life stage:

NOEC = 32 ng/L survival at day 28 (conservative NOEC)

NOEC ≥ 3200 ng/L hatch, length and dry weight

9

Toxicity to sediment dwelling midge, Chironomus riparius

OECD 218

28 day NOEC(development/emergence) = 890 mg/Kg (sediment dry weight)

28 day LOEC(development/emergence) > 890 mg/Kg (sediment dry weight)

10

NOEC   No Observed Effect Concentration

LOEC   Lowest Observed Effect Concentration

EC50    the concentration of the test substance that results in a 50% effect

LC50    the concentration of the test substance that results in a 50% mortality


Environmental risk classification (PEC/PNEC ratio)

Data from both long and short-term ecotoxicology studies are available for Budesonide to derive a PNEC. As per ECHA guidelines (ref 11), the preferable method to derive the PNEC is to apply an assessment factor to the long-term data. In this case, long term data is available for three trophic levels (ref. 4, 5, 6 & 9) which includes a fish full life cycle study.


The fish full life cycle study with zebrafish was purchased from a third party as part of a post approval commitment for a Budesonide containing product. AstraZeneca maintains that the overall quality of the study is questionable and the results observed are uncertain and inconsistent.


In the reported fish life-cycle test no significant effects on reproduction were

observed in the F0-generation. There were also no observed effects on the two biomarkers, vitellogenin and 11-keto testosterone concentrations, in blood plasma. Histopathological evaluation of female fish gonads showed an increase of ovum debris and inflammation of ovary tissue, which was considered to have impacted on egg quality at 1000 ng/L and above. However, the biological relevance remains unclear since there was no significant impact on the apical reproduction endpoints; time to spawning, total egg production, eggs per female, fertilisation rate, or hatching.


There was no impact on male gonad morphology. There were no statistically significant effects on the F0 hatching success nor the early life-stage (day 28)

survival or length endpoints. A statistically significant effect for F0 length in the 3200 ng/L concentration was observed at day 56, however this was transient and no significant differences in length were observed at termination of the F0 generation. There were also no significant effects on survival or sex ratio at the termination of the F0 generation. However, when separated by sex, a statistically significant effect on weight was observed at 3200 ng/L in female fish, only.


In the F1-generation, there were no statistically significant effects on hatching success or early life-stage growth (day 28 weight and length). There was a reduction in F1 survival at a concentration of 100 ng/L Budesonide at day 28. Although this was statistically significant, the result is a net loss of one fish compared to control, there was no clear dose response at higher concentrations and the biological mechanism of action is unknown. Further, it appears that the control fish may have performed better than typical for that laboratory, leaving the reliability open to significant questions.


The lowest NOEC from this study, the day 28 survival NOEC of 32 ng/L, based on specific survival effects in the F1-generation fish has no known mode of action and is considered overly conservative. The growth effect (NOEC = 1000 ng/L), albeit limited to females and to the weight parameter only, is considered more mechanistically appropriate and is therefore proposed as a more relevant, yet still conservative endpoint.


In conclusion, there were no effects on reproduction endpoints considered to be related to administration of Budesonide in this study. Survival of the F1-generation was determined to be the most sensitive endpoint driving the overall study NOEC. Yet, it is considered that the lack of dose response and potential effects of study design on the statistical outcome have impacted the ability to interpret the data. However, in line with the regulatory environmental risk assessment and to take a precautionary approach, the day 28 survival NOEC of 32 ng/L is taken as the overall NOEC for the study.


To calculate the PNECconservative using the day 28 survival NOEC of 32ng/L (equivalent to 0.032µg/L) an assessment factor of 10 is applied, in accordance with ECHA guidance (Ref. 11). 


PNECconservative = 0.032/10 = 0.0032 μg/L


For data comparison purposes, an additional, mechanistically appropriate PNEC is also derived from the fish study, using the NOEC for female weight (1000 ng/L), to better characterise the risk of Budesonide. To calculate the PNEC mechanistic using the mechanistically appropriate NOEC of 1000ng/L (equivalent to 1µg/L) an assessment factor of 10 is applied, in accordance with ECHA guidance (Ref. 11). 


PNECmechanistic = 1/10 = 0.1 μg/L


Prior to the purchase of the fish life cycle study, only acute data was available for three trophic levels. For all three species, the EC50 values were greater than the highest test concentration and the limit of solubility of budesonide in the test medium.  To further scrutinize the data collected, a PNEC value based on acute data is also considered, using the lowest limit of solubility of budesonide in the test media, reported for the algal study. The PNEC is based on the lowest >EC50 value of 8.6mg/L (equivalent to 8600ug/L) and an assessment factor of 1000 is applied, in accordance with ECHA guidance (Ref. 11). 


PNECacute = 8600/1000 = 8.6 μg/L


Environmental risk classification (PEC/PNEC ratio)

As discussed, there are three proposed PNECs available to calculate the PEC/PNEC ratio, as shown in the table below.


 

PNEC

PEC

PEC/PNEC ratio

Environmental Risk

PNECconservative

0.0032

0.008

2.5

moderate

PNECmechanistic

0.1

0.08

insignificant

PNECacute

8.6

0.0009

insignificant

It is acknowledged that the worst case data in the table above is generated from the PNECconservative, however due to the unreliability of the fish full life cycle study it is deemed inappropriate to define the environmental risk of Budesonide using this value. As the PNECmechanistic is also generated from data collected in the same study, it is therefore not possible to justify the use of this value to assign the environmental risk statement.


Despite the unreliability of the data collected in the fish full life cycle study, the available data does point toward a chronic sensitivity to fish therefore it is also not appropriate to use the PNECacute data to conclude the environmental risk.


Due to the questionable reliability of the fish full life cycle study, AstraZeneca outsourced a new study in 2020. Until this new data is available, it is concluded that there is insufficient data available to assess environmental impact of Budesonide at this time. Data is expected to be available from this study by Q3 2023, at which point a PNEC can be derived to assign an environmental risk statement.


This justifies the use of:

Risk of environmental impact of Budesonide cannot be excluded, since there is not sufficient ecotoxicity data available.

In Swedish: Risk för miljöpåverkan av Budesonide kan inte uteslutas då det inte finns tillräckliga ekotoxikologiska data.


Environmental Fate Data


Environmental Fate Data for Budesonide


Study Type

Method

Result

Reference

Determination of ready biodegradability

OECD301F

Degradation after 28 days <2.2 %

Not readily biodegradable

12

Adsorption/desorption to sediments, soils

and sludge

OECD106

Mean ± SD Kd (ads) (5 soils) = 34.6 ± 16.6

Mean ± SD Koc (ads) (5 soils) = 1629 ± 1734

13


Aerobic transformation in aquatic sediment systems

OECD308

HOM DT50 (water) = 6.9 days

LOM DT50 (water) = 6.45 days

HOM DT50 (total system) = 18.1 days*

LOM DT50 (total system) = 12.5 days

HOM 14CO2 (98 DAT) = 54.8% AR

LOM 14CO2 (98 DAT) = 86.2% AR


<15% of applied radioactivity remaining as parent compound (0% in water + 3.8%* in sediment) at the end of the study

14

* Results calculated for the sum of [4-14C]Budesonide and M23 as [4-14C]Budesonide could not be sufficiently separated from its metabolite M23 by the HPLC method employed.


Degradation

Biotic degradation

The aerobic biodegradation of Budesonide was assessed according to the OECD 301F Test. Results of this test indicates that Budesonide is not readily biodegradable.


The adsorption and desorption of Budesonide to five soils of differing characteristics was assessed in accordance with the OECD 106 Test Guideline. The reported Kd values ranged from 20 to 66 L/kg, with a derived mean of 34.6 L/kg. The corresponding Koc values were reported as ranging from 394 to 5049 L/kg with a derived mean of 1629 L/kg. Based on these results, Budesonide is not expected to partition significantly to sludge solids during sewage treatment processes.


The degradation of Budesonide in aquatic sediment systems was investigated according to the OECD 308 Test Guideline.The degradation of radiolabeled Budesonide was investigated in a low organic matter (LOM) content (river) versus a high organic matter (HOM) content (pond) water-sediment system under both, aerobic and anaerobic conditions, over a 98-day testing period. Only the results for the aerobic test vessels are discussed here.


The test item was applied to the water layer and, at day 0, 94.3% and 91.5% of applied radioactivity (AR) were present in the water of the LOM and HOM vessels, respectively. The amount of radiolabel in the water layer decreased to 7.8% AR (LOM) and 9.6% AR (HOM) at 98 days after treatment (DAT).


The amount of radioactivity associated with the sediment phase peaked at 30 DAT (49% AR in LOM, 69% in HOM) and subsequently decreased to 19% AR in LOM and 37% AR in HOM by the end of the study. The amount of Budesonide parent remaining in the total system test was 1.9% (in LOM). In the HOM pond system, Budesonide could not be sufficiently separated from metabolite M23, and therefore could not be quantified separately. At 98 DAT the amount of Budesonide + M23 was 3.8% AR. The study showed significant mineralization, with cumulative 14CO2 accounting for 86.2% AR and 54.8% AR in the LOM and HOM systems, respectively. All mass balances were acceptable.


Four major metabolites (>10% AR) were found in all systems (water and sediment in both river and pond systems) as either major or minor metabolites. These were identified by mass spectrometry.


The total system degradation half-life of Budesonide in the LOM (river) system was 12.5 days. In the HOM (pond) system, due to poor chromatographic separation, the degradation half-life of Budesonide was calculated from the sum of Budesonide and M23 and a conservative total system DT50 of 18.1 days was derived.


As the highest DT50 values reported passes the criteria of DT50 ≤ 32d for the total system, and less than 15% Budesonide was remaining as the parent compound at the end of the study the following phrase is therefore assigned: Budesonide is degraded in the environment

In Swedish: Budesonide bryts ned i miljön.


Physical Chemistry Data

Study Type


Method


Result


Reference


Solubility Water


Unknown


14 mg/L at 25oC


15

Octanol-Water Partition Coefficient


OECD107


Log Pow = 3.45


16

Budesonide is not ionisable within the environmentally relevant pH range.  The Log octanol-water partition coefficient is 3.45, measured at pH 7.19. 


Since Log P < 4, budesonide has low potential to bioaccumulate and the phrase “Budesonide has low potential for bioaccumulation” is assigned.


In Swedish: Budesonid har låg potential att bioackumuleras.


Bioaccumulation Data

Study Type

Method

Result

Reference

Bioaccumulation in tissues of carp

Cyprinus carpio

OECD305 

BCFL at 3μg/L = 9 ± 3

Not bioaccumulative in fish 

17


A fish bioconcentration study was conducted in carp, Cyprinus carpio according to the OECD 305 Test Guideline. During the uptake phase, fish were exposed at nominal concentrations of 0.3 and 3.0 μg/L for 28 days. A steady state concentration was reached for both test concentrations after 3 days of exposure. The whole body bioconcentration factor at steady state (BCFss) was normalised for the lipid content and reported as 8 ± 3 at 0.3 μg/L and 9 ± 3 at 3.0 μg/L of Budesonide. In the absence of any significant uptake, a depuration period was not required.


As the BCF was reported <500 the phrase “Budesonide has low potential for bioaccumulation” is assigned.


In Swedish: Budesonid har låg potential att bioackumuleras.


References

  1. Fass.se (2012).  Environmental classification of pharmaceuticals at www.fass.se: Guidance for pharmaceutical companies https://www.fass.se/pdf/Environmental_classification_of_pharmaceuticals-120816.pdf

  2. Investigator’s Brochure. Drug Substance Budesonide/formoterol. Project Code D5890000000. Edition Number 9. Date 31 May 2016.

  3. Budesonide: Activated sludge respiration inhibition test. R Harrigan & P Curtis-Jackson. Brixham Environmental Laboratory Report No BR0451/B. May 2011

  4. Budesonide: Toxicity to the green alga Selenastrum capricornutum. Bowles A.J. Brixham Environmental Laboratory Report BL8078/B. May 2005.

  5. Budesonide: Toxicity to green algae Pseudokirchneriella subcapitata determined in a growth inhibition study. Erica Tediosi, Desirée Garagna. ChemService S.r.l. Controlli e Ricerche Report 165/2013. July 2013.

  6. Budesonide: Daphnia magna reproduction test under semi-static conditions. Erica Tediosi. ChemService S.r.l. Controlli e Ricerche Report 164/2013. September 2013.

  7. Budesonide: Acute toxicity to Daphnia magna. Bowles A.J. Brixham Environmental Laboratory Report BL8079/B. May 2005.

  8. Budesonide: Acute toxicity to rainbow trout (Oncorhynchus mykiss). Bowles A.J. Brixham Environmental Laboratory Report BL8080/B. May 2005.

  9. Budesonide: A Life cycle test with the Zebrafish (Danio rerio) under flow through conditions. Dipl. Ing. Matthias Teigeler. Fraunhofer Institute for Molecular Biology and Applied Ecology IME. June 2014

  10. Sediment-water chironomid toxicity test using sediment spiked with Budesonide. M.J.E. Desmares-Koopmans, Bachelor, ERT. Charles River Laboratories Den Bosch B.V. Project 509587. July 2016.

  11. ECHA (European Chemicals Agency) 2008. Guidance on information requirements and chemical safety assessment.  Chapter R.10: Characterisation of dose [concentration]-response for environment http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_en.htm

  12. Budesonide: Ready biodegradability in a manometric respirometry test. Erica Tediosi ChemService S.r.l. Controlli e Ricerche Report CH-166/2013. July 2013

  13. Budesonide: Determination of the adsorption / desorption coefficient Koc. Stefano Paronuzzi Ticco. ChemService S.r.l. Controlli e Ricerche Report 190/2013. September 2013.

  14. [4-14C]Budesonide – Degradation in Two Different Aquatic Systems under Aerobic and Anaerobic Conditions. Dr. Rafal Piskorski. Innovative Environmental Services (IES) Ltd. May 2016.

  15. Budesonid - preformuleringsrapport. Report no. 83 – 014. Draco, Lund, Sweden. 1 February 1983.

  16. Budesonide: Determination of the partition coefficient (n-octanol/water). Simona Nichetti. ChemService S.r.l. Controlli e Ricerche Report 169/2013. June 2013.

  17. Bioaccumulation in fish with Budesonide (flow-through, aqueous exposure). L.M. Bouwman, MSc. Charles River Den Bosch B.V. Project 509585. August 2016